 | Up a level |
Hilberink, Jacobien R; van Zeventer, Isabelle A; Chitu, Dana A; Pabst, Thomas; Klein, Saskia K; Stussi, Georg; Griskevicius, Laimonas; Valk, Peter J M; Cloos, Jacqueline; van de Loosdrecht, Arjan A; Breems, Dimitri; van Lammeren-Venema, Danielle; Boersma, Rinske; Jongen-Lavrencic, Mojca; Fehr, Martin; Hoogendoorn, Mels; Manz, Markus G; Söhne, Maaike; van Marwijk Kooy, Rien; Deeren, Dries; ... (2023). Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine. Blood cancer journal, 13(1), p. 93. Springer Nature 10.1038/s41408-023-00850-6
Grob, Tim; Al Hinai, Adil S A; Sanders, Mathijs A; Kavelaars, François G; Rijken, Melissa; Gradowska, Patrycja L; Biemond, Bart J; Breems, Dimitri A; Maertens, Johan; van Marwijk Kooy, Marinus; Pabst, Thomas; de Weerdt, Okke; Ossenkoppele, Gert J; van de Loosdrecht, Arjan A; Huls, Gerwin A; Cornelissen, Jan J; Beverloo, H Berna; Löwenberg, Bob; Jongen-Lavrencic, Mojca and Valk, Peter J M (2022). Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood, 139(15), pp. 2347-2354. American Society of Hematology 10.1182/blood.2021014472
Löwenberg, Bob; Pabst, Thomas; Maertens, Johan; Gradowska, Patrycja; Biemond, Bart J; Spertini, Olivier; Vellenga, Edo; Griskevicius, Laimonas; Tick, Lidwine W; Jongen-Lavrencic, Mojca; van Marwijk Kooy, Marinus; Vekemans, Marie-Christiane; van der Velden, Walter J F M; Beverloo, Berna; Michaux, Lucienne; Graux, Carlos; Deeren, Dries; de Weerdt, Okke; van Esser, Joost W J; Bargetzi, Mario; ... (2021). Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial. Blood advances, 5(4), pp. 1110-1121. American Society of Hematology 10.1182/bloodadvances.2020003855
Janssen, Jeroen; Löwenberg, Bob; Manz, Markus; Bargetzi, Mario; Biemond, Bart; Borne, Peter von dem; Breems, Dimitri; Brouwer, Rolf; Chalandon, Yves; Deeren, Dries; Efthymiou, Anna; Gjertsen, Bjørn-Tore; Graux, Carlos; Gregor, Michael; Heim, Dominik; Hess, Urs; Hoogendoorn, Mels; Jaspers, Aurelie; Jie, Asiong; Jongen-Lavrencic, Mojca; ... (2021). Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS. Cancers, 13(4) MDPI AG 10.3390/cancers13040672
Huls, Gerwin; Chitu, Dana A; Pabst, Thomas; Klein, Saskia K; Stussi, Georg; Griskevicius, Laimonas; Valk, Peter J M; Cloos, Jacqueline; van de Loosdrecht, Arjan A; Breems, Dimitri; van Lammeren-Venema, Danielle; van Zeventer, Isabelle; Boersma, Rinske; Jongen-Lavrencic, Mojca; Fehr, Martin; Hoogendoorn, Mels; Manz, Markus G; Söhne, Maaike; van Marwijk Kooy, Rien; Deeren, Dries; ... (2020). Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS. Blood advances, 4(18), pp. 4267-4277. American Society of Hematology 10.1182/bloodadvances.2020002846
Zeijlemaker, Wendelien; Grob, Tim; Meijer, Rosa; Hanekamp, Diana; Kelder, Angèle; Carbaat-Ham, Jannemieke C; Oussoren-Brockhoff, Yvonne J M; Snel, Alexander N; Veldhuizen, Dennis; Scholten, Willemijn J; Maertens, Johan; Breems, Dimitri A; Pabst Müller, Thomas Niklaus; Manz, Markus G; van der Velden, Vincent H J; Slomp, Jennichjen; Preijers, Frank; Cloos, Jacqueline; van de Loosdrecht, Arjan A; Löwenberg, Bob; ... (2019). CD34CD38 leukemic stem cell frequency to predict outcome in acute myeloid leukemia. Leukemia, 33(5), pp. 1102-1112. Nature Publishing Group 10.1038/s41375-018-0326-3
Jongen-Lavrencic, Mojca; Grob, Tim; Hanekamp, Diana; Kavelaars, François G; Al Hinai, Adil; Zeilemaker, Annelieke; Erpelinck-Verschueren, Claudia A J; Gradowska, Patrycja L; Meijer, Rosa; Cloos, Jacqueline; Biemond, Bart J; Graux, Carlos; van Marwijk Kooy, Marinus; Manz, Markus G; Pabst Müller, Thomas Niklaus; Passweg, Jakob R; Havelange, Violaine; Ossenkoppele, Gert J; Sanders, Mathijs A; Schuurhuis, Gerrit J; ... (2018). Molecular Minimal Residual Disease in Acute Myeloid Leukemia. New England journal of medicine NEJM, 378(13), pp. 1189-1199. Massachusetts Medical Society MMS 10.1056/NEJMoa1716863
Versluis, Jurjen; Kalin, Burak; Zeijlemaker, Wendelien; Passweg, Jakob; Graux, Carlos; Manz, Markus G; Vekemans, Marie-Christiane; Biemond, Bart J; Legdeur, Marie-Cecile J C; Kooy, Marinus van Marwijk; de Weerdt, Okke; Wijermans, Pierre W; Hoogendoorn, Mels; Bargetzi, Mario J; Kuball, Juergen; Schouten, Harry C; van der Velden, Vincent H J; Janssen, Jeroen J W M; Pabst, Thomas; Lowenberg, Bob; ... (2017). Graft-Versus-Leukemia Effect of Allogeneic Stem-Cell Transplantation and Minimal Residual Disease in Patients With Acute Myeloid Leukemia in First Complete Remission. JCO precision oncology, 1, pp. 1-13. American Society of Clinical Oncology 10.1200/PO.17.00078
Löwenberg, Bob; Pabst, Thomas; Maertens, Johan; van Norden, Yvette; Biemond, Bart J; Schouten, Harry C; Spertini, Olivier; Vellenga, Edo; Graux, Carlos; Havelange, Violaine; de Greef, Georgine E; de Weerdt, Okke; Legdeur, Marie-Cecile J C; Kuball, Juergen; Kooy, Marinus van Marwijk; Gjertsen, Bjorn T; Jongen-Lavrencic, Mojca; van de Loosdrecht, Arjan A; van Lammeren-Venema, Daniëlle; Hodossy, Beata; ... (2017). Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML. Blood, 129(12), pp. 1636-1645. American Society of Hematology 10.1182/blood-2016-10-740613
Ossenkoppele, Gert J; Stussi, Georg; Maertens, Johan; van Montfort, Kees; Biemond, Bart J; Breems, Dimitri; Ferrant, August; Graux, Carlos; de Greef, Georgine E; Halkes, C J M; Hoogendoorn, Mels; Hollestein, Rene M; Jongen-Lavrencic, Mojca; Levin, Mark D; van de Loosdrecht, Arjan A; van Marwijk Kooij, Marinus; van Norden, Yvette; Pabst, Thomas; Schouten, Harry C; Vellenga, Edo; ... (2012). Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK). Blood, 120(24), pp. 4706-11. Washington, D.C.: American Society of Hematology 10.1182/blood-2012-04-420596
Löwenberg, Bob; Beck, Joachim; Graux, Carlos; van Putten, Wim; Schouten, Harry C; Verdonck, Leo F; Ferrant, Augustin; Sonneveld, Pieter; Jongen-Lavrencic, Mojca; von Lilienfeld-Toal, Marie; Biemond, Bart J; Vellenga, Edo; Breems, Dimitri; de Muijnck, Hilde; Schaafsma, Ron; Verhoef, Gregor; Döhner, Hartmut; Gratwohl, Alois; Pabst, Thomas; Ossenkoppele, Gert J; ... (2010). Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. Blood, 115(13), pp. 2586-91. Washington, D.C.: American Society of Hematology 10.1182/blood-2009-10-246470
Löwenberg, Bob; Ossenkoppele, Gert J; van Putten, Wim; Schouten, Harry C; Graux, Carlos; Ferrant, Augustin; Sonneveld, Pieter; Maertens, Johan; Jongen-Lavrencic, Mojca; von Lilienfeld-Toal, Marie; Biemond, Bart J; Vellenga, Edo; van Marwijk Kooy, Marinus; Verdonck, Leo F; Beck, Joachim; Döhner, Hartmut; Gratwohl, Alois; Pabst, Thomas; Verhoef, Gregor (2009). High-dose daunorubicin in older patients with acute myeloid leukemia. New England journal of medicine NEJM, 361(13), pp. 1235-48. Waltham, Mass.: Massachusetts Medical Society MMS 10.1056/NEJMoa0901409
